Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 28, 2022

Trastuzumab Deruxtecan for Anti-HER2 Therapy–Naïve HER2-Low Gastric or Gastroesophageal Junction Adenocarcinoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
J. Clin. Oncol 2022 Nov 15;[EPub Ahead of Print], K Yamaguchi, YJ Bang, S Iwasa, N Sugimoto, MH Ryu, D Sakai, HC Chung, H Kawakami, H Yabusaki, J Lee, T Shimoyama, KW Lee, K Saito, Y Kawaguchi, T Kamio, A Kojima, M Sugihara, K Shitara

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading